Prosecution Insights
Last updated: May 29, 2026

Xizang Haisco Pharmaceutical Co., Ltd.

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (60%)
2
Easy (40%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
§102 only1 (20%)
§112 only2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MOORE, SUSANNA 1 68.1% +31.8%
RAO, PADMAJA S 1 69.5% +35.9%
WILLIS, DOUGLAS M 1 82.6% +19.7%
YOO, SUN JAE 1 71.0% +0.0%
KATAKAM, SUDHAKAR 1 75.0% +23.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18269670 FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF WILLIS, DOUGLAS M 8d overdue

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18262459 CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM RAO, PADMAJA S 111d overdue
17906555 ORAL PHARMACEUTICAL COMPOSITION KATAKAM, SUDHAKAR 110d overdue
18558159 PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF MOORE, SUSANNA 53d overdue
18269670 FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF WILLIS, DOUGLAS M 8d overdue

Top Art Units

Art UnitApps
1624 2
1627 1
1621 1
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18558159 PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF MOORE, SUSANNA 1624 §103 Non-Final OA 53d overdue Pending Oct 30, 2023
18262459 CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM RAO, PADMAJA S 1627 §112 Non-Final OA 111d overdue Pending Jul 21, 2023
18269670 FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF WILLIS, DOUGLAS M 1624 §112 Non-Final OA 8d overdue Pending Jun 26, 2023
18015309 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF YOO, SUN JAE 1621 §102 Final Rejection 39d Pending Jan 09, 2023
17906555 ORAL PHARMACEUTICAL COMPOSITION KATAKAM, SUDHAKAR 1658 §103 Non-Final OA 110d overdue Pending Sep 16, 2022

Managing Xizang Haisco Pharmaceutical Co., Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month